TREVOSE, Pa.--(BUSINESS WIRE)--Lannett Company, Inc. (the “Company” or “Lannett”) today announced that it and certain of its subsidiaries have successfully emerged from their Chapter 11 cases following the confirmation of its Plan of Reorganization (the “Plan”) on June 8, 2023.
Lannett's Generic Solifenacin Succinate Receives Approval in the U.S.
TREVOSE, Pa., Jan. 25, 2023 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2023 second quarter on Wednesday, February 1, 2023, after the market closes. Lannett management will host a conference call that same afternoon at 4:30 p.m. Eastern Time to review the company's performance.
Enforcement Report - Week of January 25, 2023
TREVOSE, Pa., Nov. 7, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Ypsomed AG, the manufacturer and supplier of the pen injector device to be used in connection with its biosimilar insulin glargine and biosimilar insulin aspart development programs, that will provide a patent sublicense to the company and its strategic alliance partner within the HEC Group of companies (HEC).
Lannett Company, Inc. has received approval from the US Food and Drug Administration (FDA) to manufacture Numbrino, the company's branded topical anesthetic product, at its main plant in Seymour, IN. The company previously manufactured Numbrino and other liquid drug products at its Carmel, NY, plant, which it sold in March of this year as part of a restructuring and cost reduction plan.
PHILADELPHIA, Oct. 21, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has received approval from the US Food and Drug Administration (FDA) to manufacture Numbrino®, the company's branded topical anesthetic product, at its main plant in Seymour, Indiana. The company previously manufactured Numbrino and other liquid drug products at its Carmel, New York plant, which it sold in March of this year as part of a restructuring and cost reduction plan.
PHILADELPHIA, Oct. 19, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has recently sold previously discontinued abbreviated new drug applications (ANDAs) for approximately $3 million to a privately held pharmaceutical company. The transaction was structured as a sale of assets. The companies also entered into a second separate agreement, under which the other party will purchase and distribute under a private label a limited number of certain other Lannett owned generic drug products.
As the nationwide Adderall shortage rolls on, two more companies are joining the long list of suppliers struggling to meet demand.
Two more pharmaceutical companies are having difficulty supplying Adderall to US patients with attention-deficit/hyperactivity disorder as shortages plague the market.